Inhalable porous particles as dual micro-nano carriers demonstrating efficient lung drug delivery for treatment of tuberculosis

Campos Pacheco, Jesús E.; Yalovenko, Tetiana; Riaz, Azra; Kotov, Nikolay; Davids, Camilla; Persson, Alva; Falkman, Peter; Feiler, Adam; Godaly, Gabriela; Johnson, C. Magnus; Ekström, Mikael; Pilkington, Georgia A.; Valetti, Sabrina

doi:10.1016/j.jconrel.2024.03.013

Cited by 6 publications

(2 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SEM images confirm the size and spherical shape of the mesoporous silica particles (MSP) ( Figure 1(A–C) ). The particle size distribution resulted to be 2.43 ± 0.13 µm as previously reported in our recent work combining image processing of electron microscopy and Elzone (coulter principle) analysis (Campos Pacheco et al., 2024 ). This is the desirable particles size range for inhalation delivery for dry powder inhalation (DPI) formulations (Liang et al., 2020 ).…”

Section: Resultssupporting

confidence: 81%

Disordered mesoporous silica particles: an emerging platform to deliver proteins to the lungs

Rocío Hernández,

Bogdanova,

Campos Pacheco

et al. 2024

Drug Delivery

Self Cite

View full text Add to dashboard Cite

Pulmonary delivery and formulation of biologics are among the more complex and growing scientific topics in drug delivery. We herein developed a dry powder formulation using disordered mesoporous silica particles (MSP) as the sole excipient and lysozyme, the most abundant antimicrobial proteins in the airways, as model protein. The MSP had the optimal size for lung deposition (2.43 ± 0.13 µm). A maximum lysozyme loading capacity (0.35 mg/mg) was achieved in 150 mM PBS, which was seven times greater than that in water. After washing and freeze-drying, we obtained a dry powder consisting of spherical, non-aggregated particles, free from residual buffer, or unabsorbed lysozyme. The presence of lysozyme was confirmed by TGA and FT-IR, while N 2 adsorption/desorption and SAXS analysis indicate that the protein is confined within the internal mesoporous structure. The dry powder exhibited excellent aerodynamic performance (fine particle fraction <5 µm of 70.32%). Lysozyme was released in simulated lung fluid in a sustained kinetics and maintaining high enzymatic activity (71–91%), whereas LYS-MSP were shown to degrade into aggregated nanoparticulate microstructures, reaching almost complete dissolution (93%) within 24 h. MSPs were nontoxic to in vitro lung epithelium. The study demonstrates disordered MSP as viable carriers to successfully deliver protein to the lungs, with high deposition and retained activity.

show abstract

Section: Resultssupporting

confidence: 81%

Disordered mesoporous silica particles: an emerging platform to deliver proteins to the lungs

Rocío Hernández,

Bogdanova,

Campos Pacheco

et al. 2024

Drug Delivery

Self Cite

View full text Add to dashboard Cite

show abstract

“…All the microparticles, obtained with a yield higher than 40 wt %, showed no significant morphological differences, having a spherical shape with a mean diameter between 2 and 3 μm (calculated from SEM images with the help of the software ImageJ and reported in Table ). Therefore, with the deposition of particles in the lung being dependent on the carrier’s physical properties including shape, size, and uniformity, these particles are suitable for potential optimal lung deposition in the lower airways. , …”

Section: Resultsmentioning

confidence: 99%

Lung Disease Management by Iloprost-Loaded Nanoparticles to Address Hyperinflammation Associated with Cystic Fibrosis

Craparo,

Cabibbo,

Scialabba

et al. 2024

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

Influence of particle diameter on aerosolization performance and release of budesonide loaded mesoporous silica particles

van der Zwaan,

Pilkington,

Frenning

et al. 2024

European Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Inhalable porous particles as dual micro-nano carriers demonstrating efficient lung drug delivery for treatment of tuberculosis

Cited by 6 publications

References 56 publications

Disordered mesoporous silica particles: an emerging platform to deliver proteins to the lungs

Disordered mesoporous silica particles: an emerging platform to deliver proteins to the lungs

Lung Disease Management by Iloprost-Loaded Nanoparticles to Address Hyperinflammation Associated with Cystic Fibrosis

Influence of particle diameter on aerosolization performance and release of budesonide loaded mesoporous silica particles

Contact Info

Product

Resources

About